HK1252815A1 - 调节lgals3bp以治疗系统性红斑狼疮的方法 - Google Patents

调节lgals3bp以治疗系统性红斑狼疮的方法 Download PDF

Info

Publication number
HK1252815A1
HK1252815A1 HK18112121.7A HK18112121A HK1252815A1 HK 1252815 A1 HK1252815 A1 HK 1252815A1 HK 18112121 A HK18112121 A HK 18112121A HK 1252815 A1 HK1252815 A1 HK 1252815A1
Authority
HK
Hong Kong
Prior art keywords
lgals3bp
patient
antibody
cells
lgals
Prior art date
Application number
HK18112121.7A
Other languages
English (en)
Chinese (zh)
Inventor
J‧德马蒂诺
J‧德馬蒂諾
J‧德里
J‧弗拉奇
N‧刘易斯
M‧吉内斯特
S‧奥吉兹
N‧劉易斯
S‧奧吉茲
Original Assignee
默克专利有限公司
默克專利有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 默克专利有限公司, 默克專利有限公司 filed Critical 默克专利有限公司
Publication of HK1252815A1 publication Critical patent/HK1252815A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18112121.7A 2015-08-31 2016-08-30 调节lgals3bp以治疗系统性红斑狼疮的方法 HK1252815A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562212163P 2015-08-31 2015-08-31
US62/212,163 2015-08-31

Publications (1)

Publication Number Publication Date
HK1252815A1 true HK1252815A1 (zh) 2019-06-06

Family

ID=56883878

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112121.7A HK1252815A1 (zh) 2015-08-31 2016-08-30 调节lgals3bp以治疗系统性红斑狼疮的方法

Country Status (9)

Country Link
US (1) US20180251559A1 (https=)
EP (1) EP3344283A1 (https=)
JP (2) JP2018526443A (https=)
CN (1) CN107921112A (https=)
AU (1) AU2016317768A1 (https=)
CA (1) CA2994180A1 (https=)
HK (1) HK1252815A1 (https=)
IL (1) IL257755A (https=)
WO (1) WO2017040464A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156448A1 (en) * 2017-02-21 2018-08-30 The Board Of Regents Of The Uiversity Of Texas System Prediction and treatment of immunotherapeutic toxicity
KR101946884B1 (ko) * 2017-04-25 2019-02-13 고려대학교 산학협력단 대사체 분석을 이용한 베체트병의 진단방법
KR102704018B1 (ko) * 2020-06-30 2024-09-06 재단법인 아산사회복지재단 Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
EP4174086A4 (en) * 2020-06-30 2024-07-24 The Asan Foundation ANTIBODIES SPECIFICALLY BINDING TO LGALS3BP AND USE THEREOF
EP4318629A4 (en) 2021-03-24 2025-11-12 Agc Inc Primer for energy storage device electrodes, primer layer formation composition, electrode for energy storage devices, and secondary battery
IL308044A (en) * 2021-05-04 2023-12-01 Novartis Ag Treatment of systemic lupus erythematosus using antibuffer antibodies
WO2025075163A1 (ja) * 2023-10-04 2025-04-10 国立大学法人東北大学 自己反応性ｄｎ２ｂ細胞が産生する自己抗体およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1247472A (zh) * 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
EP1455813B1 (en) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
ES2244270A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2011119185A1 (en) * 2010-03-26 2011-09-29 La Jolla Institute For Allergy And Immunology Methods of inhibiting inflammation and inflammatory diseases using gal-3bp (btbd17b, lgals3bp, galectin-3 binding protein, mac-2 binding protein)
US20130052198A1 (en) * 2010-03-29 2013-02-28 The General Hospital Corporation Anti-inflammatory factors
WO2012074396A1 (en) * 2010-11-30 2012-06-07 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle

Also Published As

Publication number Publication date
JP2018526443A (ja) 2018-09-13
CA2994180A1 (en) 2017-03-09
EP3344283A1 (en) 2018-07-11
IL257755A (en) 2018-04-30
WO2017040464A1 (en) 2017-03-09
AU2016317768A1 (en) 2018-02-22
JP2021050217A (ja) 2021-04-01
US20180251559A1 (en) 2018-09-06
CN107921112A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
HK1252815A1 (zh) 调节lgals3bp以治疗系统性红斑狼疮的方法
Barrat et al. Development of TLR inhibitors for the treatment of autoimmune diseases
Liu et al. Immunodominant fragments of myelin basic protein initiate T cell-dependent pain
US10940126B2 (en) Inhibition of IL-8 in the treatment of pain and/or bone loss
Domingo Overlapping effects of new monoclonal antibodies for severe asthma
JP2009203245A (ja) 免疫複合体関連疾患を処置するための方法および組成物
JP2016035474A (ja) 炎症および自己免疫疾患を治療するための組成物および方法
Mockus et al. Encephalitogenic and regulatory CD8 T cells in multiple sclerosis and its animal models
Yu et al. The neuroprotective effect of treatment of valproic Acid in acute spinal cord injury
Xu et al. OTULIN is a new target of EA treatment in the alleviation of brain injury and glial cell activation via suppression of the NF-κB signalling pathway in acute ischaemic stroke rats
US20170100456A1 (en) Methods and compositions for immunomodulation
US20140127231A1 (en) p38 MAPK Pathway Inhibitors as Female-Specific Therapeutics
Seasons et al. Ultrasound and neuroinflammation: immune modulation via the heat shock response
Petratos et al. Novel therapeutic targets for axonal degeneration in multiple sclerosis
EP3652309A1 (en) Method for managing pain
JP7351835B2 (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
Summers et al. Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis
Lukic et al. Damage-associated molecular patterns-emerging targets for biologic therapy of childhood arthritides
US9718879B2 (en) Methods of treating pain by inhibition of VGF activity
Singh et al. Tuning immune suppression in systemic autoimmunity with self-derived peptides
Akhtaria et al. Immunopathogenesis of systemic lupus erythematosus
EP3316886A1 (en) Methods and compounds for the alleviation and/or prevention of pain
Alferink Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity
Kubo et al. Crosstalk between the immune and central nervous system with special reference to drug development
Drijvers et al. Integrating Current Thinking on Peripheral B-Cell Tolerance in Lupus